Document is current
Any future updates will be listed below
-
Authors
Damhofer, Helene
Tatar, Tülin
Southgate, Benjamin
Scarneo, Scott
Agger, Karl
Shlyueva, Daria
Uhrbom, Lene http://orcid.org/0000-0001-8595-5698
Morrison, Gillian M.
Hughes, Philip F.
Haystead, Timothy
Pollard, Steven M. http://orcid.org/0000-0001-6428-0492
Helin, Kristian http://orcid.org/0000-0003-1975-6097
- License Information
-
More Information
Article History
Received: 18 November 2023
Revised: 2 April 2024
Accepted: 5 April 2024
First Online: 17 April 2024
Competing interests
: TH, PFH, and SS are co-founders of Eydisbio Inc, a startup company that has licensed the patents related to the HS-276 molecule, used in this study. SP is a co-founder and scientific advisor to Cellinta Ltd. KH is a co-founder of Dania Therapeutics, and a scientific advisor to Hannibal Innovation. BS is now employed as a Senior Bioinformatician at Zifo RnD solutions. TH, PFH, and SS are co-inventors of three US patent filings related to the HS-276 scaffold. The remaining authors declare no competing interests.
: Surgically resected glioblastoma tumor tissue was acquired under the Lothian NRS BioResource study (REC protocol no. 15/ES/0094) and the Genomic and expression profiling of brain tumors study (REC protocols no. 08/H0716/16). Written informed consent of all patients donating tissue specimen was obtained.
